Pathogenic mechanisms and latest therapeutic approaches for radiation-induced lung injury: A narrative review

The treatment of thoracic tumors with ionizing radiation can cause radiation-induced lung injury (RILI), which includes radiation pneumonitis and radiation-induced pulmonary fibrosis. Preventing RILI is crucial for controlling tumor growth and improving quality of life. However, the serious adverse...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Critical reviews in oncology/hematology 2024-10, Vol.202, p.104461, Article 104461
Hauptverfasser: Chang, Sitong, Lv, Jincai, Wang, Xuanzhong, Su, Jing, Bian, Chenbin, Zheng, Zhuangzhuang, Yu, Huiyuan, Bao, Jindian, Xin, Ying, Jiang, Xin
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The treatment of thoracic tumors with ionizing radiation can cause radiation-induced lung injury (RILI), which includes radiation pneumonitis and radiation-induced pulmonary fibrosis. Preventing RILI is crucial for controlling tumor growth and improving quality of life. However, the serious adverse effects of traditional RILI treatment methods remain a major obstacle, necessitating the development of novel treatment options that are both safe and effective. This review summarizes the molecular mechanisms of RILI and explores novel treatment options, including natural compounds, gene therapy, nanomaterials, and mesenchymal stem cells. These recent experimental approaches show potential as effective prevention and treatment options for RILI in clinical practice. •For patients who have used RILI drugs for a long time, the toxic side effects of the drugs can lead to poor tolerance and limited application. Natural compounds with low toxic side effects such as PM014, glucosamine and ulinastatin have been shown to have potential as radiation protectants, sustained-release agents or therapeutic agents.•Most previous treatment strategies targeted only the early stages of RILI, with few effective treatments for the nearly irreversible stage of RPF. Fortunately, ABT-263, FG-3019 and MSCs have been shown to have the potential to reverse lung remodeling.•Other new therapeutic approaches, including gene therapy and nanomaterials, have also provided new insights into the treatment of RILI.
ISSN:1040-8428
1879-0461
1879-0461
DOI:10.1016/j.critrevonc.2024.104461